Hospital
Mercy Health Partners
Mercy Health Partners was paid $8.01M by Medicaid between Jan 2018 and Dec 2024, across 151 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoMERCY HEALTH PARTNERS
SHELBY, MI 49455
SHELBY, MI 49455
33aNPI1285662981assigned 06/29/2006
33bProvider typeCritical Access Hospital
28Total paid$8.01M
24GClaims256,882
24DCodes billed151
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Michigan
Rank by total paid#10 of 31
Median peer was paid$6.03M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,889 | $658K | |
| 2019 | 24,074 | $588K | |
| 2020 | 25,302 | $806K | |
| 2021 | 47,843 | $1.60M | |
| 2022 | 50,032 | $1.76M | |
| 2023 | 47,127 | $1.43M | |
| 2024incomplete | 37,615 | $1.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 10,616 | 10,200 | $1.66M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 4,897 | 4,634 | $1.12M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 2,586 | 2,469 | $830K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.0% | 5,816 | 5,658 | $561K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.0% | 3,880 | 3,397 | $479K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.7% | 7,247 | 6,971 | $460K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.1% | 1,807 | 1,769 | $249K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.0% | 1,269 | 1,244 | $238K |
| 71046 | Radiologic examination, chest; 2 views | 2.3% | 4,189 | 3,954 | $186K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.9% | 1,303 | 1,283 | $149K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.6% | 2,254 | 2,131 | $130K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 3,893 | 3,754 | $123K |
139 more codes
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.3% | 1,664 | $104K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 2,652 | $103K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.3% | 5,076 | $102K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.1% | 1,830 | $92K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 734 | $87K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.1% | 2,690 | $85K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 8,851 | $85K |
| 80053 | Comprehensive metabolic panel | 1.0% | 18,798 | $83K |
| 80061 | Lipid panel | 1.0% | 8,632 | $80K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,895 | $62K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,892 | $62K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,579 | $57K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 17,969 | $55K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,609 | $54K |
| 71045 | Radiologic examination, chest; single view | <1% | 906 | $50K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,536 | $39K |
| 36415 | Collection of venous blood by venipuncture | <1% | 22,904 | $37K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,516 | $35K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,829 | $29K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 269 | $26K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 328 | $24K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 73 | $22K |
| 87480 | <1% | 1,865 | $22K | |
| 87660 | <1% | 1,862 | $22K | |
| 87510 | <1% | 1,806 | $21K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 607 | $21K |
| 87070 | <1% | 3,917 | $20K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,539 | $19K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 583 | $19K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 113 | $17K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 600 | $15K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,861 | $13K |
| 94060 | <1% | 73 | $13K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 675 | $13K |
| 94726 | <1% | 199 | $11K | |
| 82607 | <1% | 1,254 | $11K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 600 | $10K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 631 | $10K |
| 73630 | <1% | 650 | $9K | |
| 82728 | <1% | 1,115 | $9K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,339 | $9K |
| 87077 | <1% | 1,927 | $9K | |
| 87186 | <1% | 1,696 | $8K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 600 | $8K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 120 | $8K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,590 | $7K |
| 84439 | <1% | 1,320 | $7K | |
| 85027 | <1% | 2,071 | $7K | |
| 83540 | <1% | 1,498 | $6K | |
| 82043 | <1% | 1,467 | $5K | |
| 86803 | <1% | 544 | $5K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 36 | $5K |
| 84466 | <1% | 590 | $5K | |
| 71271 | <1% | 73 | $5K | |
| 73564 | <1% | 163 | $5K | |
| 81001 | <1% | 5,029 | $5K | |
| 83880 | <1% | 568 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 334 | $4K |
| 83735 | <1% | 3,024 | $4K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 235 | $4K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 55 | $4K |
| 87088 | <1% | 867 | $3K | |
| 82550 | <1% | 1,051 | $3K | |
| 82570 | <1% | 832 | $3K | |
| 87081 | <1% | 1,673 | $3K | |
| 81003 | <1% | 3,810 | $3K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 107 | $3K |
| 87147 | <1% | 965 | $3K | |
| 85610 | <1% | 2,307 | $3K | |
| 86900 | <1% | 91 | $2K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $2K |
| 86140 | <1% | 1,008 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 117 | $2K |
| 83550 | <1% | 316 | $2K | |
| 83690 | <1% | 3,013 | $2K | |
| 73610 | <1% | 202 | $2K | |
| 94010 | <1% | 40 | $2K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 12 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $2K |
| 0002A | <1% | 49 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 16 | $1K |
| 0012A | <1% | 38 | $1K | |
| 73130 | <1% | 194 | $1K | |
| 0001A | <1% | 59 | $1K | |
| 73110 | <1% | 58 | $1K | |
| 85730 | <1% | 1,279 | $963.93 | |
| 85652 | <1% | 752 | $961.08 | |
| 73030 | <1% | 48 | $885.48 | |
| 84100 | <1% | 819 | $850.58 | |
| 0011A | <1% | 44 | $773.72 | |
| 84703 | <1% | 2,495 | $664.49 | |
| 87807 | <1% | 375 | $620.37 | |
| 86780 | <1% | 66 | $615.03 | |
| 72100 | <1% | 41 | $595.23 | |
| 72110 | <1% | 13 | $375.78 | |
| 84702 | <1% | 54 | $316.83 | |
| 85007 | <1% | 135 | $302.26 | |
| 83655 | <1% | 25 | $261.89 | |
| 82746 | <1% | 25 | $252.40 | |
| 84484 | <1% | 2,267 | $216.51 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 982 | $198.14 |
| 85379 | <1% | 490 | $196.47 | |
| 84403 | <1% | 12 | $164.61 | |
| 82248 | <1% | 83 | $158.68 | |
| 86038 | <1% | 14 | $97.06 | |
| 85651 | <1% | 63 | $87.55 | |
| 83605 | <1% | 1,332 | $84.48 | |
| 86039 | <1% | 12 | $78.92 | |
| 86850 | <1% | 28 | $70.68 | |
| 86901 | <1% | 91 | $49.48 | |
| 86592 | <1% | 13 | $43.11 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,423 | $35.27 |
| 87205 | <1% | 13 | $25.64 | |
| 84550 | <1% | 12 | $22.41 | |
| 87040 | <1% | 90 | $16.60 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,494 | $14.90 |
| 82553 | <1% | 105 | $7.26 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,362 | $6.49 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 362 | $2.86 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,785 | $2.05 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 944 | $1.10 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 519 | $0.91 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 83 | $0.00 |
| 94729 | 0% | 198 | $0.00 | |
| 94664 | 0% | 57 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 35 | $0.00 |
| 76376 | 0% | 65 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 269 | $0.00 |
| J3490 | Unclassified drugs | 0% | 128 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 410 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 112 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 126 | $0.00 |
| 96376 | 0% | 73 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 253 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 26 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 28 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 47 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 64 | $0.00 |
| A9270 | Non-covered item or service | 0% | 174 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialALLORE, GARY (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Mercy Health Partners | Muskegon, MI | $98.26M |
| Mercy Health Partners | Muskegon, MI | $2.39M |
| Mercy Health Partners | Muskegon, MI | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.